VM Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The company has a collaboration with Bayer for the research and development of evaluating potential future production of iodine to be used in contrast media drugs. Voyageur Pharmaceuticals Ltd. was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. The company is headquartered in Calgary, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Voyageur Pharmaceuticals (CVE: VM)
›
Voyageur Pharmaceuticals (CVE: VM) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 0.1150 CAD on 19 November 2026, down 23.3% over 52 weeks. Its 52-week range is 0.0700 CAD to 0.1950 CAD: the price is 41.0% below the high and 64.3% above the low.
Its market capitalisation is 26.17M CAD.
Voyageur Pharmaceuticals reports return on equity of -282.1% and revenue up 32.7% year over year.
It holds more cash than debt, a net cash position of 1.77M CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 5 April 2027.